title: [Efficacy of postoperative simple chemotherapy and concurrent chemoradiotherapy in FIGO stage IB2-IIB cervical cancer].
abstract: OBJECTIVE
  To evaluate the effectiveness of neoadjuvant chemotherapy (NAC) followed by radical hysterectomy plus postoperative chemotherapy but no radiotherapy for stage IB2-IIB cervical cancer.
  
  
  METHODS
  Seventy-nine patients with stage IB2-IIB cervical cancer were treated with NAC followed by radical hysterectomy. According to different adjuvant therapies, patients were divided into postoperative chemotherapy group (47 cases) and postoperative radiotherapy/concurrent chemoradiotherapy group (32 cases). Regimens for NAC and postoperative chemotherapy were BIP (bleomycin+ ifosfamide+ cisplatin/carboplatin) or TP (paclitaxel+ cisplatin/carboplatin). An average of 1.1±0.3 cycles of NAC and 3.4±1.2 cycles of postoperative chemotherapy were prescribed.
  
  
  RESULTS
  Toxicities due to chemotherapy were generally tolerable. Overall response rate of NAC was 88.6%. With a median follow-up period of 42 months, the three-year progression-free survival rates of the two groups were 88.5% and 84.3%, the total survival rates were 90.3% and 86.4%, respectively. There was no statistically significant difference. The recurrent rates were 10.6% and 21.8% in the two groups. In the absence of radiotherapy, pelvic recurrence was observed in two patients; the other three had distant metastases.
  
  
  CONCLUSIONS
  The results indicate that NAC followed by surgery plus postoperative chemotherapy but no radiotherapy offers a viable option in the treatment of stage IB2-IIB cervical cancer. The patients can tolerate the side effects of chemotherapy with better efficacy.
authors.affiliation: Department of Obstetrics and Gynecology, Peking University First Hospital, Peking 100034, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Ma
authors.affiliation: Department of Preventive Medicine, Northwestern University, Chicago 60611, USA.
authors.forename: Yi-he
authors.initials: YH
authors.lastname: Yang
authors.forename: Xi
authors.initials: X
authors.lastname: Yang
authors.forename: Zhao-Yi
authors.initials: ZY
authors.lastname: Feng
authors.affiliation: Fujian Provincial Tumor Hospital, Fuzhou, 350014, China.
authors.forename: Tong-yu
authors.initials: TY
authors.lastname: Liu
authors.forename: Hong-wu
authors.initials: HW
authors.lastname: Wen
authors.forename: Qin-ping
authors.initials: QP
authors.lastname: Liao
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D007069:Ifosfamide / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D017239:Paclitaxel; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D043823:Taxoids; D001761:Bleomycin; D017239:Paclitaxel; D002945:Cisplatin; D007069:Ifosfamide